IBM WebSphere Application Server 7.0/8.0/8.5/9.0 UNC Path privileges management
| CVSS Meta Temp Score | Current Exploit Price (≈) | CTI Interest Score |
|---|---|---|
| 6.5 | $5k-$25k | 0.00 |
Summary
A vulnerability marked as critical has been reported in IBM WebSphere Application Server 7.0/8.0/8.5/9.0. This vulnerability affects unknown code of the component UNC Path Handler. Performing a manipulation results in privileges management. This vulnerability is identified as CVE-2020-4534. The attack is only possible with local access. There is not any exploit available.
Details
A vulnerability was found in IBM WebSphere Application Server 7.0/8.0/8.5/9.0 (Application Server Software). It has been classified as critical. This affects an unknown code of the component UNC Path Handler. The manipulation with an unknown input leads to a privileges management vulnerability. CWE is classifying the issue as CWE-269. The product does not properly assign, modify, track, or check privileges for an actor, creating an unintended sphere of control for that actor. This is going to have an impact on confidentiality, integrity, and availability. The summary by CVE is:
IBM WebSphere Application Server 7.0, 8.0, 8.5, and 9.0 could allow a local authenticated attacker to gain elevated privileges on the system, caused by improper handling of UNC paths. By scheduling a task with a specially-crafted UNC path, an attacker could exploit this vulnerability to execute arbitrary code with higher privileges. IBM X-Force ID: 182808.
The weakness was released 08/03/2020 (Website). The advisory is shared at ibm.com. This vulnerability is uniquely identified as CVE-2020-4534 since 12/30/2019. An attack has to be approached locally. A authentication is needed for exploitation. Neither technical details nor an exploit are publicly available. The price for an exploit might be around USD $5k-$25k at the moment (estimation calculated on 08/03/2020). MITRE ATT&CK project uses the attack technique T1068 for this issue.
There is no information about possible countermeasures known. It may be suggested to replace the affected object with an alternative product.
If you want to get the best quality for vulnerability data then you always have to consider VulDB.
Product
Type
Vendor
Name
Version
License
Website
- Vendor: https://www.ibm.com/
CPE 2.3
CPE 2.2
CVSSv4
VulDB Vector: 🔍VulDB Reliability: 🔍
CVSSv3
VulDB Meta Base Score: 6.5VulDB Meta Temp Score: 6.5
VulDB Base Score: 5.3
VulDB Temp Score: 5.3
VulDB Vector: 🔍
VulDB Reliability: 🔍
NVD Base Score: 7.8
NVD Vector: 🔍
CVSSv2
| AV | AC | Au | C | I | A |
|---|---|---|---|---|---|
| 💳 | 💳 | 💳 | 💳 | 💳 | 💳 |
| 💳 | 💳 | 💳 | 💳 | 💳 | 💳 |
| 💳 | 💳 | 💳 | 💳 | 💳 | 💳 |
| Vector | Complexity | Authentication | Confidentiality | Integrity | Availability |
|---|---|---|---|---|---|
| Unlock | Unlock | Unlock | Unlock | Unlock | Unlock |
| Unlock | Unlock | Unlock | Unlock | Unlock | Unlock |
| Unlock | Unlock | Unlock | Unlock | Unlock | Unlock |
VulDB Base Score: 🔍
VulDB Temp Score: 🔍
VulDB Reliability: 🔍
Exploiting
Class: Privileges managementCWE: CWE-269 / CWE-266
CAPEC: 🔍
ATT&CK: 🔍
Physical: Partially
Local: Yes
Remote: No
Availability: 🔍
Status: Not defined
EPSS Score: 🔍
EPSS Percentile: 🔍
Price Prediction: 🔍
Current Price Estimation: 🔍
| 0-Day | Unlock | Unlock | Unlock | Unlock |
|---|---|---|---|---|
| Today | Unlock | Unlock | Unlock | Unlock |
Threat Intelligence
Interest: 🔍Active Actors: 🔍
Active APT Groups: 🔍
Countermeasures
Recommended: no mitigation knownStatus: 🔍
0-Day Time: 🔍
Timeline
12/30/2019 🔍08/03/2020 🔍
08/03/2020 🔍
11/06/2020 🔍
Sources
Vendor: ibm.comAdvisory: ibm.com
Status: Not defined
Confirmation: 🔍
CVE: CVE-2020-4534 (🔍)
GCVE (CVE): GCVE-0-2020-4534
GCVE (VulDB): GCVE-100-159261
X-Force: 182808
Entry
Created: 08/03/2020 18:40Updated: 11/06/2020 22:50
Changes: 08/03/2020 18:40 (38), 08/03/2020 18:45 (12), 11/06/2020 22:45 (2), 11/06/2020 22:50 (1)
Complete: 🔍
Cache ID: 216::103
If you want to get the best quality for vulnerability data then you always have to consider VulDB.
No comments yet. Languages: en.
Please log in to comment.